EP1648469A4 - Antiglucocorticoide für die behandlung von katatonie - Google Patents

Antiglucocorticoide für die behandlung von katatonie

Info

Publication number
EP1648469A4
EP1648469A4 EP04779017A EP04779017A EP1648469A4 EP 1648469 A4 EP1648469 A4 EP 1648469A4 EP 04779017 A EP04779017 A EP 04779017A EP 04779017 A EP04779017 A EP 04779017A EP 1648469 A4 EP1648469 A4 EP 1648469A4
Authority
EP
European Patent Office
Prior art keywords
antiglucocorticoids
catatonia
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04779017A
Other languages
English (en)
French (fr)
Other versions
EP1648469A2 (de
Inventor
Joseph K Belanoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corcept Therapeutics Inc
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of EP1648469A2 publication Critical patent/EP1648469A2/de
Publication of EP1648469A4 publication Critical patent/EP1648469A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
EP04779017A 2003-07-23 2004-07-23 Antiglucocorticoide für die behandlung von katatonie Withdrawn EP1648469A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48967103P 2003-07-23 2003-07-23
PCT/US2004/023761 WO2005009388A2 (en) 2003-07-23 2004-07-23 Antiglucocorticoids for the treatment of catatonia

Publications (2)

Publication Number Publication Date
EP1648469A2 EP1648469A2 (de) 2006-04-26
EP1648469A4 true EP1648469A4 (de) 2010-04-14

Family

ID=34102917

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04779017A Withdrawn EP1648469A4 (de) 2003-07-23 2004-07-23 Antiglucocorticoide für die behandlung von katatonie

Country Status (5)

Country Link
US (1) US8097606B2 (de)
EP (1) EP1648469A4 (de)
AU (1) AU2004259011B2 (de)
CA (1) CA2532594C (de)
WO (1) WO2005009388A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA016494B1 (ru) 2007-02-02 2012-05-30 Пфайзер Продактс Инк. (2R,4αS,10αR)-4α-БЕНЗИЛ-7-((2-МЕТИЛПИРИДИН-3-ИЛ)КАРБАМОИЛ)-2-(ТРИФТОРМЕТИЛ)-1,2,3,4,4α,9,10,10α-ОКТАГИДРОФЕНАНТРЕН-2-ИЛДИГИДРОФОСФАТ ИЛИ ЕГО СОЛЬ
EP1987814A1 (de) * 2007-04-30 2008-11-05 Exelgyn Pharmazeutische Mifepristonzusammensetzungen und Herstellungsverfahren dafür
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999017779A1 (en) * 1997-10-06 1999-04-15 The Board Of Trustees Of Leland Stanford Jr. University Methods for treating psychosis associated with glucocorticoid related dysfunction
WO2002076390A2 (en) * 2001-03-23 2002-10-03 Corcept Therapeutics, Inc. Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
EP1499321A2 (de) * 2002-04-29 2005-01-26 Corcept Therapeutics, Inc. Verfahren zur verstärkung des therapeutischen ansprechens auf elektrokonvulsive therapie (ect)
EP1534299A2 (de) * 2002-07-02 2005-06-01 Corcept Therapeutics, Inc. Verfahren zur behandlung von psychose im zusammenhang mit einer therapie mit interferon-alpha

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468741A (en) * 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
CA2166332C (en) * 1993-08-04 2005-05-10 Bernardus Wynand Machijs Marie Peeters Antiglucocorticoid steroids for the treatment of anxiety disorders
EP0903146A1 (de) * 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (21-0H-60P) als ANitoglucocortikoid
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
KR20010040935A (ko) 1998-02-13 2001-05-15 스티븐 에프. 웨인스톡 글루코코르티코이드 선택적인 소염제
US6262042B1 (en) * 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
WO1999063976A2 (en) 1998-06-08 1999-12-16 Karo Bio Ab Liver-selective glucocorticoid antagonist for treating diabetes
CZ304203B6 (cs) 1999-04-30 2014-01-02 Pfizer Products Inc. Modulátor glukokortikoidního receptoru a léčivo pro léčbu zánětlivé choroby s jeho obsahem
AU4903101A (en) 1999-11-30 2001-07-09 Cornell Research Foundation Inc. Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
GB0029102D0 (en) 2000-11-29 2001-01-10 Karobio Ab Compounds active at the glucocorticoid receptor
GB0029100D0 (en) 2000-11-29 2001-01-10 Karobio Ab Compounds active at the glucocorticoid receptor
DE60233111D1 (de) 2001-02-14 2009-09-10 Karobio Ab Glucocorticoid-rezeptoren-modulatoren
EP1453495A2 (de) 2001-11-23 2004-09-08 Akzo Nobel N.V. Verfahren zur behandlung schwerer depression unter verwendung von glucocorticoid-rezeptor-antagonisten
EP1567089B1 (de) 2002-11-15 2014-10-08 Synecor, LLC Polymere endoprothese

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999017779A1 (en) * 1997-10-06 1999-04-15 The Board Of Trustees Of Leland Stanford Jr. University Methods for treating psychosis associated with glucocorticoid related dysfunction
WO2002076390A2 (en) * 2001-03-23 2002-10-03 Corcept Therapeutics, Inc. Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
EP1499321A2 (de) * 2002-04-29 2005-01-26 Corcept Therapeutics, Inc. Verfahren zur verstärkung des therapeutischen ansprechens auf elektrokonvulsive therapie (ect)
EP1534299A2 (de) * 2002-07-02 2005-06-01 Corcept Therapeutics, Inc. Verfahren zur behandlung von psychose im zusammenhang mit einer therapie mit interferon-alpha

Also Published As

Publication number Publication date
EP1648469A2 (de) 2006-04-26
AU2004259011A1 (en) 2005-02-03
US8097606B2 (en) 2012-01-17
US20050080066A1 (en) 2005-04-14
CA2532594A1 (en) 2005-02-03
CA2532594C (en) 2012-10-02
WO2005009388A2 (en) 2005-02-03
WO2005009388A3 (en) 2005-06-16
AU2004259011B2 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
EP1689485A4 (de) Kardioelektromagnetische behanldung
HK1095529A1 (en) Methods for the treatment of endometriosis
GB0316912D0 (en) Therapeutic treatment
GB0320806D0 (en) Therapeutic treatment
GB0326486D0 (en) Combination treatment
GB0312407D0 (en) Treatment
GB0329275D0 (en) Therapeutic treatment
GB0307863D0 (en) Therapeutic treatment
EP1648469A4 (de) Antiglucocorticoide für die behandlung von katatonie
GB0300428D0 (en) Medical treatment
GB0313772D0 (en) Therapeutic treatment
GB0327493D0 (en) Treatment medicament
GB0306165D0 (en) Medical treatment
GB0325957D0 (en) The treatment of pain
GB0322014D0 (en) The treatment of pain
GB0307740D0 (en) Treatment
GB0304531D0 (en) Treatment
GB0321233D0 (en) Therapeutic treatment
GB0318552D0 (en) Therapeutic treatment
GB0318323D0 (en) Therapeutic treatment
GB0321234D0 (en) Therapeutic treatment
GB0321235D0 (en) Therapeutic treatment
GB0321236D0 (en) Therapeutic treatment
GB0321650D0 (en) Therapeutic treatment
GB0322000D0 (en) Therapeutic treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060209

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CORCEPT THERAPEUTICS, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20100317

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/18 20060101ALI20100311BHEP

Ipc: A61K 31/568 20060101ALI20100311BHEP

Ipc: A61K 31/58 20060101ALI20100311BHEP

Ipc: A61K 31/56 20060101AFI20050627BHEP

Ipc: A61K 31/05 20060101ALI20100311BHEP

Ipc: A61P 31/14 20060101ALI20100311BHEP

Ipc: A61K 31/00 20060101ALI20100311BHEP

Ipc: A61K 31/567 20060101ALI20100311BHEP

17Q First examination report despatched

Effective date: 20110211

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130423